Company intelligence / Profile preview

BioGaia New Sciences

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

The company’s first product, BioGaia Aldermis, is a probiotic ointment designed for dry and sensitive skin in infants and children; it is currently commercially available in North America. No detailed clinical trial data have been released, but the company emphasizes science-driven, clinically relevant results in product development[1][2][5].

Therapeutic areas: Dermatology
Modalities: Live biotherapeutic product therapyMicrobial therapyProbiotic
Industry: Biotech

Beyond the preview

Go deeper on BioGaia New Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioGaia New Sciences.

Explore the full profile